期刊文献+

利拉鲁肽治疗肥胖型2型糖尿病疗效观察 被引量:1

Clinical Observation on Liraglutide Treatment of Obesity type 2 diabetes
下载PDF
导出
摘要 目的:观察利拉鲁肽治疗肥胖型2型糖尿病的临床效果。方法选取2013年6月~2014年6月我院收治的肥胖型2型糖尿病患者15例作为研究对象,采用利拉鲁肽治疗,比较治疗前后患者的各血糖及体重变化情况。结果治疗后,患者的血糖降低程度以及体重变化显著优于治疗前,差异具有统计学意义(0.01<P<0.05)。结论利拉鲁肽治疗肥胖型2型糖尿病疗效确切,可明显降低患者的体重和血糖水平,建议广泛推广与使用。 Objective To explore the efect of of liraglutide in treatment of Obesity diabetes 2.Methods 15 cases of patients with type 2 diabetes obesity were randomly divided into two groups.They were hospitalized in 2013 to 2014 in June.The control group and the treatment group,the blood glucose and body weight changes before and after treatment was compared.Results The treatment group was better than the control,there was statistical significance(P〈0.05).Conclusion The efects on 2 diabetes obese treatment,can significantly reduce body weight and blood glucose.We can promote this treating method.
作者 曹德云
出处 《中国卫生标准管理》 2015年第2期54-55,共2页 China Health Standard Management
关键词 2型糖尿病 肥胖型 利拉鲁肽 Type 2 diabetes Obesity Liraglutide
  • 相关文献

参考文献4

二级参考文献22

  • 1万禧,林玉印,魏善斌.不规则岩石试件抗拉强度的套筒致裂试验研究[J].中国矿业大学学报,1994,23(1):90-95. 被引量:27
  • 2廖二元.内分泌医师手册[M].北京:糖尿病之友杂志社出版,2011:585. 被引量:2
  • 3Nielsen LL,Oung AA,Parkes DG.Pharmacology of exenatide (synthetic ex endin-4):a potential therapeutic for improved glycemic control of type 2 diabetes[J].Regul Pept,2004,117(2):77-88. 被引量:1
  • 4Mane M,Shaw J,Brandle M,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)[J].Diabet Med,2009,26(3):268-278. 被引量:1
  • 5Nauck M,Frid A,Hermansen K,etal.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD (liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,32(1):84-90. 被引量:1
  • 6Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono):a randomised,52-week,phase Ⅲ,double-blind,parallel-treatment trial[J].Lancet,2009,373 (9662):473-481. 被引量:1
  • 7Zinman B,Gerich J,Buse J B,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met + TZD)[J].Diabetes Care,2009,32 (7):1224-1230. 被引量:1
  • 8Russell JD,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with mefformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU):a randomised controlled trial[J].Diabetologia,2009,52(10):2046-2055. 被引量:1
  • 9BuseJ B,Rosenstock J,Sesti G,et al.Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised,parallel-group,multinational,open-label trial (LEAD-6)[J].Lancet,2009,374(9683):39-40. 被引量:1
  • 10Ban K,Noyan A,Hoefer J,et al.Cardioprotective and vasodialatory actions of glucagon-like peptide 1 receptor are medicated through both glucagon-like peptide 1 receptor-dependent and independent pathways[J].Circulation,2008,117 (18):2340-2350. 被引量:1

共引文献16

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部